DEA as Schedule 3 now vs China and other countries I have been saying that China has their foot to the floor in advanced pharmaceutical cannabinoid research. The DEA was holding back R&D work in the U.S. This presents yet ANOTHER opportunity for LABS as now academic research institutions and pharmaceutical companies in the U.S. can procure materials required from LABS to start playing catch up to research work in other countries such as China, Germany, Brazil, Netherlands, etc.
NOW THE FDA CAN FINALLY APPROVE THE 505(b)2 NEW DRUG APPLICATION FROM LABS
STAY TUNED, THERE IS NOW MORE NEWS ON THE WAY!!!